Longeveron (LGVN) Total Non-Current Liabilities (2022 - 2026)

Longeveron's (LGVN) quarterly Total Non-Current Liabilities came in at $838000.0 in Q1 2026, down 13.25% year-on-year from $966000.0 in Q1 2025, and up 67.94% quarter-over-quarter from $499000.0 in Q4 2025.

Longeveron (LGVN) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends

Longeveron's Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $838000.0 for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities fell 13.25% year-over-year to $838000.0 in Q1 2026; TTM through Mar 2026 was $838000.0, a 13.25% decrease from a year earlier, with the FY2025 full-year figure at $499000.0, down 54.18% from the prior year.
  • Total Non-Current Liabilities grew to $838000.0 in Q1 2026 per LGVN's latest filing, from $499000.0 in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $2.0 million in Q4 2022 and bottomed at $499000.0 in Q4 2025.
  • The 5-year median for Total Non-Current Liabilities is $1.2 million (2024), against an average of $1.2 million.
  • Across the five-year window, Total Non-Current Liabilities slumped 54.18% in 2025 and fell 13.25% in 2026, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $2.0 million in 2022, then slipped by 29.05% to $1.4 million in 2023, then dropped by 24.79% to $1.1 million in 2024, then slumped by 54.18% to $499000.0 in 2025, then surged by 67.94% to $838000.0 in 2026.
  • Per Business Quant, the three latest LGVN Total Non-Current Liabilities figures stand at $838000.0 (Q1 2026), $499000.0 (Q4 2025), and $651000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Longeveron 3.97 Mn -11.79 Mn 264,000.00 838,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 838,000.00
Dec 31, 2025 499,000.00
Sep 30, 2025 651,000.00
Jun 30, 2025 809,000.00
Mar 31, 2025 966,000.00
Dec 31, 2024 1.09 Mn
Sep 30, 2024 1.18 Mn
Jun 30, 2024 1.27 Mn
Mar 31, 2024 1.36 Mn
Dec 31, 2023 1.45 Mn
Sep 30, 2023 1.60 Mn
Jun 30, 2023 1.75 Mn
Dec 31, 2022 2.04 Mn